← board
ESPR
Esperion Therapeutics, Inc.distress 2/10 · well-funded / low risk$3.180%today-22% from 52w high
Metabolic / Obesity 1
Lead: Hypercholesterolemia
Revenue
$80M
Liquidity
$156M
Runway
8.6 yrs
Shares 1y
+28%
Price & events
+0.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+1.0%
1W
+1.0%
1M
+43.2%
3M
-3.6%
6M
+167.2%
1Y
+26.7%
2Y
-82.6%
5Y
-88.5%
All
Overview
- Market Cap
- $818.63M
- Volume
- 0
- 52 Week Range
- $0.98 – $4.08
- Total Shares
- 257.43M
- Float Shares
- 234.89M
- Short %
- 6.87%
- % Held by Insiders
- 0.90%
- % Held by Institutions
- 71.54%
- Beta
- 1.06
Pipeline stages · 1 programs
Bempedoic acid
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-06-04 | Phase 2 | Bempedoic acid | Hypercholesterolemia | 31 | completed |
Catalyst news & presentations · 3
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-15partnershipHSR waiting period expired for merger with ArchiMed affiliate.SEC 8-K
- 2026-05-01partnershipMerger agreement with Essence Parent Inc. for acquisition at $3.16 per share plus contingent value rights.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $3 (+1% upside) · 3 analysts
- 2026-05-04NeedhamBuy → Hold
- 2026-05-01HC Wainwright & Co.Buy → Neutral
- 2026-03-13CitizensMarket Outperform
- 2026-03-03NeedhamBuy
- 2025-11-25Piper SandlerOverweight
- 2025-09-19HC Wainwright & Co.Buy
Competitors — Hypercholesterolemia
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- ARWRARROWHEAD PHARMACEUTICALS, INC.$12.3B · D3
- NAMSNewAmsterdam Pharma Co N.V.$3.6B · D0
- NAMSWNewAmsterdam Pharma Co N.V.$2.3B · D0
- EDITEditas Medicine, Inc.$266M · D6
- SLNCFSilence Therapeutics plc$213M · D5
Recent news
- 2026-07-23Esperion Therapeutics, Inc. SEC Filing (Jul 23, 2026) - Stock Titan
- 2026-07-18Why Did ESPR Stock Surge 58% In Pre-Market Today? - Stocktwits
- 2026-07-18ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
- 2026-07-16Esperion Therapeutics, Inc. SEC Filing (Jul 16, 2026) - Stock Titan
- 2026-07-14News On Esperion Therapeutics Inc. (ESPR) Now Under ESPR.XX - Moomoo
- 2026-07-14Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake - Stock Titan
- 2026-07-14Esperion Therapeutics, Inc.(NasdaqGM: ESPR) dropped from S&P Global BMI Index - marketscreener.com
- 2026-07-14Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.